|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 8/08/16 Opko Health, Inc. 10-Q 6/30/16 80:10M |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 702K
2: EX-10.2 Material Contract HTML 237K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 24K
13: R1 Document and Entity Information HTML 41K
14: R2 Condensed Consolidated Balance Sheets HTML 108K
15: R3 Condensed Consolidated Balance Sheets HTML 31K
(Parenthetical)
16: R4 Condensed Consolidated Statements of Operations HTML 103K
17: R5 Condensed Consolidated Statements of Comprehensive HTML 45K
Income (Loss)
18: R6 Condensed Consolidated Statements of Cash Flows HTML 144K
19: R7 Condensed Consolidated Statements of Cash Flows HTML 25K
(Parenthetical)
20: R8 Business and Organization HTML 34K
21: R9 Summary of Significant Accounting Policies HTML 79K
22: R10 Earnings (Loss) Per Share HTML 81K
23: R11 Composition of Certain Financial Statement HTML 131K
Captions
24: R12 Acquisitions, Investments and Licenses HTML 123K
25: R13 Debt HTML 128K
26: R14 Accumulated Other Comprehensive Income (Loss) HTML 38K
27: R15 Fair Value Measurements HTML 146K
28: R16 Derivative Contracts HTML 62K
29: R17 Related Party Transactions HTML 33K
30: R18 Commitments and Contingencies HTML 38K
31: R19 Strategic Alliances HTML 55K
32: R20 Segments HTML 160K
33: R21 Subsequent Events HTML 29K
34: R22 Summary of Significant Accounting Policies HTML 133K
(Policies)
35: R23 Earnings (Loss) Per Share Computation of Basic and HTML 74K
Diluted Earnings (Loss) Per Share (Tables)
36: R24 Composition of Certain Financial Statement HTML 132K
Captions (Tables)
37: R25 Acquisitions, Investments and Licenses (Tables) HTML 96K
38: R26 Debt (Tables) HTML 111K
39: R27 Accumulated Other Comprehensive Income (Loss) HTML 35K
(Tables)
40: R28 Fair Value Measurements (Tables) HTML 144K
41: R29 Derivative Contracts (Tables) HTML 57K
42: R30 Segments (Tables) HTML 152K
43: R31 Business and Organization (Details) HTML 52K
44: R32 Summary of Significant Accounting Policies HTML 131K
(Details)
45: R33 Earnings (Loss) Per Share - Computation of HTML 64K
Earnings (Loss) Per Share (Details)
46: R34 Earnings (Loss) Per Share - Narrative (Details) HTML 35K
47: R35 Composition of Certain Financial Statement HTML 143K
Captions (Details)
48: R36 Composition of Certain Financial Statement HTML 61K
Captions - Changes in Goodwill (Details)
49: R37 Acquisitions, Investments and Licenses - HTML 109K
Acquisition Narrative (Details)
50: R38 Acquisitions, Investments and Licenses - HTML 89K
Bio-Reference Purchase Price Allocation (Details)
51: R39 Acquisitions, Investments and Licenses - Schedule HTML 33K
of Pro Forma (Details)
52: R40 Acquisitions, Investments and Licenses - EirGen HTML 65K
Purchase Price Allocation (Details)
53: R41 Acquisitions, Investments and Licenses - Summary HTML 36K
of Investments (Details)
54: R42 Acquisitions, Investments and Licenses - Equity HTML 53K
Method Investments Narrative (Details)
55: R43 Acquisitions, Investments and Licenses - Available HTML 48K
for Sale Investments, Sale of Investments and
Warrants and Options Narrative (Details)
56: R44 Acquisitions, Investments and Licenses - Variable HTML 66K
Interest Entities Narrative (Details)
57: R45 Acquisitions, Investments and Licenses - Other HTML 53K
Narrative (Details)
58: R46 Debt - Narrative (Details) HTML 153K
59: R47 Debt - Notes (Details) HTML 52K
60: R48 Debt - Inputs Used In Lattice Model (Details) HTML 41K
61: R49 Debt - Fair Value Of Embedded Derivatives HTML 30K
(Details)
62: R50 Debt - Lines Of Credit (Details) HTML 60K
63: R51 Debt - Mortgage Notes And Other Debt (Details) HTML 32K
64: R52 Accumulated Other Comprehensive Income (Loss) HTML 37K
(Details)
65: R53 Fair Value Measurements - Summary Of Investments HTML 36K
(Details)
66: R54 Fair Value Measurements - Assets And Liabilities HTML 63K
Measured At Fair Value (Details)
67: R55 Fair Value Measurements - Notes (Details) HTML 30K
68: R56 Fair Value Measurements - Level 3 Reconciliation HTML 36K
(Details)
69: R57 Fair Value Measurements - Narrative (Details) HTML 34K
70: R58 Derivative Contracts - Balance Sheet Component HTML 40K
(Details)
71: R59 Derivative Contracts - Derivative Gains (Losses) HTML 34K
(Details)
72: R60 Related Party Transactions (Details) HTML 113K
73: R61 Commitments and Contingencies (Details) HTML 41K
74: R62 Strategic Alliances (Details) HTML 136K
75: R63 Segments - Narrative (Details) HTML 43K
76: R64 Segments - Operations and Assets Information HTML 79K
(Details)
77: R65 Subsequent Events (Details) HTML 60K
79: XML IDEA XML File -- Filing Summary XML 141K
78: EXCEL IDEA Workbook of Financial Reports XLSX 116K
7: EX-101.INS XBRL Instance -- opk-20160630 XML 3.06M
9: EX-101.CAL XBRL Calculations -- opk-20160630_cal XML 251K
10: EX-101.DEF XBRL Definitions -- opk-20160630_def XML 1.13M
11: EX-101.LAB XBRL Labels -- opk-20160630_lab XML 2.13M
12: EX-101.PRE XBRL Presentations -- opk-20160630_pre XML 1.35M
8: EX-101.SCH XBRL Schema -- opk-20160630 XSD 197K
80: ZIP XBRL Zipped Folder -- 0000944809-16-000025-xbrl Zip 331K
| Exhibit |
(1) | I have reviewed this Quarterly Report on Form 10-Q of OPKO Health, Inc.; |
(2) | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
(3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
(4) | The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the
registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
(5) | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date:
August 8, 2016 | |
Chief Executive Officer | |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/8/16 | 8-K | ||
| For Period end: | 6/30/16 | 4, 8-K | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/01/24 Opko Health, Inc. 10-K 12/31/23 122:18M RDG Filings/FA 2/27/23 Opko Health, Inc. 10-K 12/31/22 121:20M 3/01/22 Opko Health, Inc. 10-K 12/31/21 110:16M 2/18/21 Opko Health, Inc. 10-K 12/31/20 111:16M |